Fate Therapeutics
FATE
54 hedge funds and large institutions have $62.7M invested in Fate Therapeutics in 2015 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 5 closing their positions.
200% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 5
70% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 10
23% more funds holding
Funds holding: 44 → 54 (+10)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
36% less capital invested
Capital invested by funds: $97.8M → $62.7M (-$35.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$1.24M |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$817K |
| 3 |
BGA
Belmont Global Advisors
Dallas,
Texas
|
+$694K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$547K |
| 5 |
Millennium Management
New York
|
+$357K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$3.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$655K |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$476K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$373K |
| 5 |
TCM
Tufton Capital Management
Hunt Valley,
Maryland
|
-$274K |
FATE Hedge Fund Activity: Q4 2015 in Review
54 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q4 2015, worth a combined $62.7M — down 36% from $97.8M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new FATE positions and 5 closed out — a net gain of 10 holders — while 17 added to existing stakes and 10 trimmed.
The largest buyer was Redmile Group, adding an estimated $1.24M. The largest seller was Highland Capital Management (Texas), exiting entirely with an estimated $3.5M sold.
- 54 institutional investors held Fate Therapeutics (FATE) as of Q4 2015, up from 44 in Q3 2015.
- Funds reported $62.7M of Fate Therapeutics stock for Q4 2015, down 36% quarter-over-quarter.
- 15 funds opened new Fate Therapeutics positions in Q4 2015 and 5 closed out, a net change of +10 holders.
- The largest Fate Therapeutics buyer in Q4 2015 was Redmile Group, an estimated $1.24M added.
- The largest Fate Therapeutics seller in Q4 2015 was Highland Capital Management (Texas), an estimated $3.5M sold.
Based on aggregated 13F filings for Q4 2015.